Metabolic scavenging by cancer cells: when the going gets tough, the tough keep eating by Michalopoulou, Evdokia et al.
Metabolic scavenging by cancer cells: when
the going gets tough, the tough keep eating
Evdokia Michalopoulou1,2, Vinay Bulusu1,2 and Jurre J Kamphorst*,1,2
1Cancer Metabolism Research Unit, Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Glasgow G61 1BD,
UK and 2Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow G61 1QH, UK
Cancer is fundamentally a disease of uncontrolled cell proliferation. Tumour metabolism has emerged as an exciting new
discipline studying how cancer cells obtain the necessary energy and cellular ‘building blocks’ to sustain growth. Glucose and
glutamine have long been regarded as the key nutrients fuelling tumour growth. However, the inhospitable tumour
microenvironment of certain cancers, like pancreatic cancer, causes the supply of these nutrients to be chronically insufficient for
the demands of proliferating cancer cells. Recent work has shown that cancer cells are able to overcome this nutrient insufficiency
by scavenging alternative substrates, particularly proteins and lipids. Here, we review recent work identifying the endocytic
process of macropinocytosis and subsequent lysosomal processing as an important substrate-acquisition route. In addition, we
discuss the impact of hypoxia on fatty acid metabolism and the relevance of exogenous lipids for supporting tumour growth as
well as the routes by which tumour cells can access these lipids. Together, these cancer-specific scavenging pathways provide a
promising opportunity for therapeutic intervention.
Unremitting cell proliferation, the true hallmark of cancer, is
metabolically demanding. It requires energy, reducing power,
and cellular ‘building blocks’ in the form of amino acids for
proteins, fatty acids for lipids and nucleotides for DNA and RNA.
Despite the inherently intimate link between proliferation and
metabolism, which was already demonstrated early on by
Warburg et al (1927, 1956), the field of cancer metabolism has
only recently risen to prominence. An important instigator
was the realisation that the observed metabolic reprogramming
in cancer cells is directly triggered by oncogenes (Deberardinis
et al, 2008). In fact, the oncogene-induced autonomous acquisition
of nutrients has been proposed to be a critical step in cellular
transformation (Pavlova and Thompson, 2016). One of the first
signalling cascades to be studied in the context of cancer
metabolism is the PI(3)K/Akt/mTOR pathway, which is often
constitutively activated in cancer (Elstrom et al, 2004; Engelman
et al, 2006). In keeping with its physiological role as the insulin
effector pathway, activation of this pathway results in enhanced
glucose uptake and increased de novo synthesis of cellular building
blocks (Figure 1A).
Recent work has emphasised that the stressful conditions of the
tumour microenvironment, with parts of the tumour periodically
experiencing limited availability of primary nutrients and
oxygen, also affect the metabolism of cancer cells. Limited
oxygen availability affects central carbon metabolism, and more
recently has been shown to compromise fatty acid synthesis
(Kamphorst et al, 2013; Young et al, 2013). The strong influence
of the microenvironment is epitomised in pancreatic cancer.
Pancreatic ductal adenocarcinomas (PDAC) are characterised
by high interstitial pressures, leading to blood vessel collapse
and diminished nutrient and oxygen delivery (Provenzano et al,
2012; Chauhan et al, 2014; Delgiorno et al, 2014). Despite this,
PDAC is one of the most aggressive cancers. Research into the
metabolism of PDAC cells revealed that they scavenge extracellular
proteins by hijacking an ancient feeding mechanism called
macropinocytosis to support metabolism and proliferation
(Figure 1B).
Scavenging of alternative nutrients, particularly macromole-
cules, has emerged as an alternative to de novo synthesis to support
proliferation of cancer cells, and has recently been included as one
of the hallmarks of cancer metabolism (Pavlova and Thompson,
2016). Here, we review recent studies on metabolic scavenging by
cancer cells, with a particular emphasis on macropinocytosis and
lipid scavenging. We also discuss remaining questions and
highlight the exciting therapeutic potential of targeting these novel
scavenging pathways.
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GOING BIG—EATING PROTEINS TO SURVIVE AND GROW
The idea that cancer cells degrade macromolecules to support
metabolism is not new. In fact, a well-established mechanism exists
by which cells degrade intracellular material: autophagy. During
autophagy, cytoplasmic macromolecules, protein aggregates
and/or organelles are sequestered into double-membraned vesicles
known as autophagosomes. These fuse with lysosomes, allowing
lysosomal enzymes (proteases, lipases, nucleases and glycosidases)
to degrade the lysosomal content. Autophagy functions as the
‘waste-disposal’ system in cells, clearing damaged macromolecules
and organelles that would otherwise become harmful. As a
consequence of lysosomal hydrolysis metabolites such as amino
acids, fatty acids, nucleosides and sugars are released from the
lysosomes, ready to be re-used for energy production or as cellular
building blocks (Rabinowitz and White, 2010).
It has been proposed that in an established tumour autophagy
promotes tumour cell survival and resistance against therapy. In
particular, multiple reports have highlighted the importance of
autophagy in the context of oncogenic Ras-driven tumours. Cells
expressing oncogenic Ras were found to have elevated basal
autophagy (Karsli-Uzunbas et al, 2014). In keeping with its
metabolic function, disrupting the autophagy machinery in these
cells led to reduced TCA cycle activity and a depletion of energy,
resulting in reduced viability during starvation conditions in vitro
and reduced tumourigenesis in vivo. It thus appears that autophagy
is particularly important for maintaining mitochondrial activity,
both by ensuring a healthy mitochondrial pool and by replenishing
the TCA cycle with autophagic breakdown products, including
amino acids like glutamine (Strohecker and White, 2014). In a
separate study, an elevation in basal autophagy was observed in
PDAC, a tumour type with a near 100% occurrence of mutant
KRAS (Yang et al, 2011). Inhibition of autophagy attenuated
proliferation of PDAC cells, and in vivo PDAC tumour progression
was similarly severely affected. This was due to increased ROS
production and decreased mitochondrial oxidative phosphoryla-
tion, again highlighting the importance of autophagy in metabo-
lism. Further evidence for increased dependence on autophagy and
lysosomal processing in PDAC was provided by a study showing
their aberrant regulation (Perera et al, 2015). Specifically, the MiT/
TFE transcription factors were found to exhibit increased nuclear
residence through shuttling by IPO8/IPO7, which led to the
upregulation of autophagy- and lysosome-promoting genes.
Disruption of these transcription factors resulted in reduced
cellular amino acid pools. From these studies it is apparent that
Ras-driven cancers, particularly PDAC, hijack autophagy to
maintain metabolic homoeostasis.
An endocytic mechanism resembling autophagy is macropinocy-
tosis. It occurs at the cell surface, where membrane ruffling leads to
the engulfment of extracellular fluid and formation of cytoplasmic
vesicles called macropinosomes (Figure 1B). A first hint at its potential
importance in cancer was provided by the finding that macro-
pinocytosis is induced by Ras. Although this observation was made
some 30 years ago, only recently was it discovered that macro-
pinocytosis functions to take in macromolecules to support
metabolism (Commisso et al, 2013). In this study it was shown that
macropinocytosis-mediated uptake of extracellular protein (albumin)
and subsequent hydrolysis provides amino acids to support central
carbon metabolism. Macropinocytosis digests extracellular material,
and because of this it accrues new biomass and hence facilitates
growth and proliferation, and not just survival. Recent work
confirmed that macropinocytosis occurs in human PDAC, and that
it enables continued growth of PDAC cells in the absence of free
essential amino acids (Kamphorst et al, 2015). Together, these reports
argue that macropinocytosis is an important mode of nutrient
acquisition in PDAC.
The regulation of autophagy is relatively well-described.
macropinocytosis, on the other hand, has until now received
much less attention, and much remains to be learned about its
regulation, especially in mammalian systems. A recent advance was
made by the establishment of a link between mTORC1 and
extracellular protein scavenging (Palm et al, 2015). In this study, it
was corroborated that cells with mutant KRAS were able to
proliferate in medium lacking leucine when albumin was provided.
Cells expressing activated Akt1 (myr-Akt1) on the other hand,
could not. Surprisingly, the authors found that while under
nutrient-replete conditions mTORC1 inhibition attenuated growth
of cells with mutant KRAS, during free amino acid-depleted
conditions it actually led to increased lysosomal degradation of
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Figure 1. Cancer cells can use two modes of metabolism to acquire
cellular ‘building blocks’ for growth. (A) An established mode, most
extensively studied in the context of PI(3)K-Akt-mTOR signalling,
involves de novo synthesis of cellular building blocks (amino acids,
nucleotides, fatty acids) from glucose and free amino acids, particularly
glutamine, for the construction of new daughter cells. (B) More
recently, an alternative mode was discovered that allows certain cancer
types (PDAC in particular) to maintain survival and proliferation in
nutrient poor conditions, by scavenging alternative nutrients,
particularly protein and lipid macromolecules. Extracellular proteins can
be consumed by an endocytic process called macropinocytosis. Lipid-
scavenging pathways are depicted in detail in Figure 2.
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extracellular protein and increased proliferation. The organism
most extensively used for macropinocytosis research is the soil-
dwelling amoebae Dictyostelium discoideum. Dictyostelium uses
macropinocytosis to feed on bacteria. Over time, lab strains with
heightened macropinocytosis have evolved, allowing them to grow
on liquid medium. Interestingly, these lab strains commonly
have mutations in a Ras-GAP (Neurofibromin 1) leading to
constitutive activation of Ras (Bloomfield et al, 2015). Various
studies in Dictyostelium have identified major regulators of
macropinocytosis such as the small GTPases Rac1 and Cdc42
(Dumontier et al, 2000). Furthermore, it has been shown that the
Arp2/3 complex along with phosphoinositide 3-kinase are required
for the formation of macropinosomes ( Hoeller et al, 2013). The
requirement for PIP3 lipids in macropinosome formation
seemingly contradicts the finding that the PI(3)K/Akt/mTOR
pathway (also depending on PIP3) is a negative regulator of
extracellular protein scavenging. However, the PI(3)Ks in both
situations are likely to be different isoforms and/or they may be
exposed to different stimuli simply because of their location
(plasma membrane surface vs macropinosome).
The regulatory complexity of macropinocytosis is likely to be of
similar scale as that of autophagy. Owing to the renewed interest,
we expect that important aspects of this process will soon be
elucidated. Beyond the regulation of macropinocytosis, however,
many questions remain. Is PDAC the only type of cancer to use
macropinocytosis as a feeding mechanism? What macromolecules
do tumour cells scavenge in vivo? Can they consume extracellular
matrix, and would that enable increased migration? Does
macropinocytosis confer resistance to therapies that inhibit
biosynthesis or angiogenesis? Arguably the most important
question is, however, does macropinocytosis itself provide a
therapeutic opportunity? Although a better understanding of
macropinocytosis will help answering this question, results so far
are promising. Because macropinosomes end up fusing with
lysosomes, inhibiting lysosomal function can inhibit extracellular
protein scavenging. The chloroquine derivative hydroxychloro-
quine (HCQ) inhibits the acidification of lysosomes and shows
promising results when combined with gemcitabine (Boone et al,
2015). At the moment, multiple clinical trials with HCQ are
ongoing. Other lysosomal inhibitors are currently being developed
and it would be extremely interesting to study their effect in
PDAC.
A radically different approach is to exploit PDAC’s taste for
protein to selectively smuggle chemotherapeutics into cancer cells
to reach high therapeutic doses (the ‘Trojan horse’ approach).
Tantalising results supporting this idea were obtained in a clinical
study with the protein–drug conjugate albumin–paclitaxel
(nab-paclitaxel). In this study with 861 patients, the combination
of nab-paclitaxel with gemcitabine significantly increased the
overall survival compared with gemcitabine treatment alone
(Goldstein et al, 2015). On the basis of these encouraging results,
further investigation into exploiting macropinocytosis for
therapeutic purposes is certainly warranted.
GREASING THE CANCER MACHINE—SCAVENGING
ACETATE, FATTY ACIDS AND LIPIDS
Fatty acids are a sine qua non for cellular proliferation. Whereas
the essential poly-unsaturated fatty acids (PUFA) can only be
obtained by uptake from dietary sources, cells have the option to
either build non-essential fatty acids from scratch or to take them
up. A considerable body of research indicates that, in contrast to
most other tissue types, many cancers engage in de novo fatty acid
synthesis. Especially cancer cells with a constitutively active
PI(3)K-Akt-mTOR axis, most commonly through loss of PTEN
or activating mutations in PI(3)K, are reliant on lipogenesis
(Porstmann et al, 2008). Signalling by mTORC1 activates the
sterol-regulatory element-binding protein family of transcription
factors (Porstmann et al, 2008), inducing the expression of the
lipogenic genes such as acetyl-CoA carboxylase (ACACA), fatty acid
synthase (FASN) and stearoyl-CoA desaturase (SCD), to facilitate
increased fatty acid biosynthesis. Further evidence for an important
role for lipogenesis in cancer has been found in the upregulation of
FASN in a variety of tumours. It is, however, important to note
that enzyme expression per se does not necessarily correlate with
the actual lipogenic flux. Cells could upregulate FASN in an effort
to maintain fatty acid biosynthesis during nutrient limitation.
The precursor for fatty acid synthesis is acetyl-CoA (AcCoA),
whose acetyl-unit in normoxic cells is derived mostly from glucose.
Hypoxia, a common occurrence in solid tumours, is known to
affect central carbon metabolism; in a HIF1-mediated suppression
of pyruvate dehydrogenase activity most glucose is shunted
towards lactate, instead of entering the TCA cycle (Kim et al,
2006; Papandreou et al, 2006). This affects AcCoA production
from glucose and how this in turn affects fatty acid synthesis has
been actively researched in recent years. A first insight into this
came from multiple publications showing that in (pseudo)hypoxic
cells fatty acids had strongly increased 13C-carbon labelling from
13C-glutamine compared with normoxic cells (Wise et al, 2011;
Metallo et al, 2012; Mullen et al, 2012). Notably, this increased
labelling occurred through the reductive production of the AcCoA
precursor citrate from glutamine-derived a-ketoglutarate, rather
than through oxidative metabolism. Later work argued that the
increased fatty acid labelling from 13C-glutamine in hypoxia can at
least partly be explained by exchange of intermediates rather than a
net synthesis flux (Fan et al, 2013). Many reactions in metabolism
are reversible, as is the reaction between a-ketoglutarate and
citrate. When using 13C-glutamine, the resulting labelled a-
ketoglutarate can mix with citrate, causing it also to become
labelled, even when there is no net synthesis of citrate from a-
ketoglutarate. As citrate itself is the precursor for AcCoA which is
used for fatty acid synthesis, it is possible that labelling of fatty
acids occurs from 13C-glutamine without a net carbon contribu-
tion. Therefore, to what degree carbon from glutamine actually
contributes to fatty acid synthesis in hypoxic cells remains debated.
As stated, reversibility of reactions is a common phenomenon in
metabolism, and this should always be considered in the
interpretation of stable-isotope-tracing experiments.
More recently another substrate that could potentially sustain
fatty acid synthesis in hypoxic cancer cells was identified: acetate.
Specifically, it was found that the enzyme generating AcCoA from
acetate, acetyl-CoA synthetase 2 (ACSS2), is frequently amplified
in a subset of cancers and is upregulated in cells exposed to
hypoxic and low serum conditions (Schug et al, 2015). Conse-
quently, labelling of lipogenic AcCoA and hence fatty acids from
13C-acetate was found to be increased in these conditions
(Kamphorst et al, 2014; Schug et al, 2015). Further work showed
a significant reduction in tumour growth upon knockdown of
ACSS2 in a breast cancer xenograft model (Schug et al, 2015), and
a significant reduction in tumour burden was found following
ACSS2 knockout in a genetically engineered mouse model of
hepatocellular carcinoma (Comerford et al, 2014). These observa-
tions clearly demonstrate the importance of ACSS2 in maintaining
tumour growth of certain cancer types. However, how exactly this
occurs, is not yet fully understood. Although a likely explanation is
that ACSS2 captures acetate as an alternative carbon source to
support biomass production when AcCoA production from
glucose is limited, formal proof for this is lacking. Direct
assessment of acetate uptake rates by cells is required to determine
if net uptake occurs in hypoxic cells and if it is higher than in
normoxic cells. This would help establish whether increased
labelling in hypoxic cells from 13C-acetate is due to increased
uptake, or simply a consequence of reduced production of AcCoA
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from glucose. In addition, as with glutamine, labelling of lipogenic
AcCoA from acetate may not track with net carbon contribution.
Such mismatch between labelling and actual carbon contribution
could happen if the turnover of protein acetylation occurs at a
much higher rate than fatty acid production, leading to exchange
as discussed above. Therefore, efforts to more accurately quantify
fluxes are required to better understand how hypoxic cells
maintain lipogenesis. Similarly, much is still to be learned about
acetate production and availability in vivo.
Beyond the changes in AcCoA production, fatty acid maturation
has also been found to be affected by hypoxic conditions.
Specifically, the desaturase responsible for the production of the
abundant fatty acid oleate, SCD, is oxygen-dependent. Our work
revealed a decrease in the cellular desaturation index (oleate/
stearate), suggesting reduced SCD activity in hypoxia, which was
confirmed by tracing experiments (Kamphorst et al, 2013). As a
consequence, hypoxic cells were more reliant on exogenous mono-
unsaturated fatty acids to maintain a viable desaturation index.
A separate study corroborated reduced SCD activity and hence
increased dependence on exogenous mono-unsaturated fatty acids
in hypoxic cancer cells (Young et al, 2013). Cells with unregulated
growth exposed to limited oxygen and serum were found to be
unable to maintain a viable desaturation index, resulting in
induction of unfolded protein response-mediated apoptosis due to
sustained endoplasmic reticulum stress.
Our work with a panel of isogenic cell lines harbouring distinct
oncogenic alterations, suggests there is variability in the response
to SCD inhibition (Kamphorst et al, 2013). Cells with constitutive
activation of the PI(3)K/Akt/mTOR pathway (through myr-Akt
expression) had a high fatty acid biosynthetic flux. These cells were
extremely sensitive to SCD inhibition due to a strongly decreasing
desaturation index and an inability to compensate by scavenging
serum lipids. Strikingly, expression of mutant Ras decreased de
novo lipogenesis and increased the ability to scavenge serum lipids.
As a result, growth of these cells was unaffected by SCD inhibition
when provided with sufficient serum. It should be noted, however,
that the effects of Ras on de novo lipogenesis and lipid scavenging
might be context and cell type dependent (Ricoult et al, 2016).
Variability in response is also seen in vivo. Silencing of SCD in
prostate orthografts strongly increased the survival of the host mice
(Peck et al, 2016). However, xenografted MiaPaCa-2 (PDAC)
tumours were entirely refractory against SCD inhibition (Daemen
et al, 2015). Thus, although certain cancer cells and tumours rely
heavily on de novo lipogenesis (either through specific oncogenic
alteration and/or a limited availability in exogenous lipids), this is
certainly not universally true in all tumour settings. On the basis of
this, interrupting lipid scavenging may prove to be an effective
approach in a subset of cancers, and especially in notoriously
hypoxic tumours.
What are the most relevant sources of fatty acids for cancer
cells, and how are they taken up? Although it is hard to establish
the availability of the various substrates in the tumour micro-
environment, some guidance can be found in plasma concentra-
tions. The free fatty acids palmitate and oleate, for instance, have
mean concentrations of 66–122 mM and 51–122 mM, respectively
(Psychogios et al, 2011). Palmitate containing lysophosphatidyl-
choline (LPC(16:0)), one of the most abundant lysolipids, has a
similar mean concentration of 106 mM, and the oleate containing
LPC(18:1) is present at approximately 40mM. Much higher
concentrations are found in cholesterol esters that are sequestered
in lipoproteins. The palmitate cholesterol ester has a reported
mean concentration of 405 mM and oleate cholesterol 750 mM. The
triglyceride content of LDLs is relatively low (o10wt%) but higher
in lower-density particles. Although lysolipid uptake and metabo-
lism remain poorly described, more is known about the
mechanisms of intake for free fatty acid and lipoproteins and
their involvement in cancer (Figure 2). One of the best
characterised fatty acid transporters is the fatty acid translocase
CD36, which facilitates transport of circulating free fatty acids
across the cell membrane. In addition, fatty acids sequestered in
lipoproteins can be released extracellularly by lipoprotein lipase
(LPL) followed by CD36-mediated uptake, or lipoproteins can be
internalised in their entirety through LDL receptor-mediated
endocytosis. Strikingly, one study found that while expression of
both LPL and CD36 in cultured cancer cells is generally low, it is
widespread in tumour tissues such as breast, liposarcoma and
prostate tissues (Kuemmerle et al, 2011). CD36 has additionally
been shown to be associated with progression of hepatocellular
carcinoma (Nath et al, 2015), and in other cancers LDL receptor
(LDLR) is upregulated, including in PDAC tumours (Guillaumond
et al, 2015). In PDAC, LDLR is highly expressed both in vitro and
in vivo. Consequently, PDAC cells maintain high levels of
cholesterol and silencing LDLR reduced cell proliferation. In
human PDAC, LDLR expression correlates with poor prognosis.
Finally, lipoprotein ingestion via macropinocytosis may also occur.
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Figure 2. Lipid-acquisition routes in cancer cells. Cancer cells can
produce non-essential fatty acids from the primary nutrients glucose
and glutamine. However, low nutrient availability and hypoxia
compromises the ability to synthesise fatty acids from these substrates
and diminishes the ability to desaturate fatty acids by the oxygen-
dependent SCD. The presence of mutant Ras also leads to decreased
desaturation by SCD. Cancer cells use acetate as an alternative
substrate for fatty acid synthesis. In addition, they acquire fatty acids
(particularly unsaturated ones) and cholesterol directly through LDLR-
mediated uptake and processing. Furthermore, free fatty acids (either
generated by lipoprotein lipase (LPL) or circulating free fatty acids) can
be transported into the cell via CD36. Lysophospholipids may also be a
physiologically relevant source for unsaturated fatty acids, but how they
are catabolised remains unknown to date.
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One question lingers: what is the availability of exogenous lipids
in the tumour microenvironment, especially in hypoxic regions
where we know fatty acid maturation is compromised? Just like
other cells, cancer cells need essential PUFA, so some supply is
absolutely necessary. One could argue that an insufficient
perfusion not only leads to a scarcity of primary nutrients and
oxygen but also of serum lipids. However, in some tumour types,
such as breast cancer, the cancer cells may be in close proximity to
adipocytes (Tan et al, 2011). Also, blood vessels in tumours are
typically poorly constructed and leaky, and tumours have
lymphatic deficiency. As a result, macromolecules and large
complexes such as albumin and lipoproteins might actually
accumulate in tumours. Detailed in vivo tracing experiments
together with systematic histological evaluation will be the way
forward in addressing these questions.
SUMMARY
The discovery that beyond glucose and glutamine cancer cells can
metabolise a variety of substrates, including macromolecules, is
both bad and good news. Bad news because it demonstrates a
degree of metabolic adaptability that likely makes biosynthetic
inhibitors have limited impact for certain tumour types. Good
news because these scavenging pathways potentially provide new
and selective therapeutic opportunities, on their own or in
combination with biosynthesis inhibitors. The collective of recent,
conceptually innovative papers has established metabolic scaven-
ging as a new paradigm. However, many important questions
remain. Does macropinocytosis only occur in pancreatic cancer?
How important is it really in supporting metabolism, in vivo? And
does it provide a mechanism of resistance to for example mTOR
inhibition? And with respect to lipid metabolism, to what degree
do various tumours in vivo depend on de novo fatty acid synthesis
vs uptake and what are the most important routes of fatty acid
acquisition? We anticipate that answers to many of these questions
will be found in the coming years, and that the therapeutic
potential of scavenging pathways will become clearer.
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